Evidence map›Paper›PMID 37333156›Full record

ArticleResearch square2023

CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity.

Dalia Haydar, Jorge Ibañez-Vega, Jeremy Chase Crawford, Ching-Heng Chou, Cliff Guy, Michaela Meehl, Zhongzhen Yi, Deanna Langfitt, Peter Vogel, Christopher DeRenzo and 4 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Dalia HaydarSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.ORCID 0000-0002-7959-2699
Jorge Ibañez-VegaSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.
Jeremy Chase CrawfordSt. Jude Children's Research Hospital, Department of Immunology, Memphis, TN, USA.
Ching-Heng ChouSt. Jude Children's Research Hospital, Department of Immunology, Memphis, TN, USA.
Cliff GuySt. Jude Children's Research Hospital, Department of Immunology, Memphis, TN, USA.
Michaela MeehlSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.
Zhongzhen YiSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.
Deanna LangfittSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.ORCID 0000-0003-0941-5360
Peter VogelSt. Jude Children's Research Hospital, Department of Pathology, Memphis, TN, USA.ORCID 0000-0002-7535-0545
Christopher DeRenzoSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.
Stephen GottschalkSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.ORCID 0000-0003-3991-7468
Martine F RousselSt. Jude Children's Research Hospital, Department of Tumor Cell Biology, Memphis, TN, USA.ORCID 0000-0002-1740-8139
Paul G ThomasSt. Jude Children's Research Hospital, Department of Immunology, Memphis, TN, USA.ORCID 0000-0001-7955-0256
Giedre KrenciuteSt. Jude Children's Research Hospital, Department of Bone Marrow Transplantation and Cellular Therapy, Memphis, TN, USA.ORCID 0000-0003-4335-0644
St. Jude Children's Research Hospital · USNational Hospital · INChildren's Research Hospital · JP

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0M
Improving genetically engineered T cells for medulloblastomasR01NS121249 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KRENCIUTE, GIEDRE · 2021 to 2025
$2.2M
Improving CAR T cell therapy for brain tumors using immune competent modelsR00CA256262 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI HAYDAR, DALIA · 2023 to 2025
$713k
Improving CAR T cell therapy for brain tumors using immune competent modelsK99CA256262 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HAYDAR, DALIA · 2021 to 2022
$250k
NCI NIH HHS K99 CA256262NCI NIH HHS P01 CA096832NCI NIH HHS P30 CA021765NCI NIH HHS R00 CA256262NINDS NIH HHS R01 NS121249
6 · The paper itself

Abstract

Understanding interactions between adoptively transferred immune cells and the tumor immune microenvironment (TIME) is critical for developing successful T-cell based immunotherapies. Here we investigated the impact of the TIME and chimeric antigen receptor (CAR) design on anti-glioma activity of B7-H3-specific CAR T-cells. We show that five out of six B7-H3 CARs with varying transmembrane, co-stimulatory, and activation domains, exhibit robust functionality

Indexed as

brain tumor immune microenvironmentbrain tumorsCAR T-cell therapychimeric antigen receptorimmunocompetent mouse modelsscRNAseq

Identifiers

PMID37333156
PMCPMC10275057
OpenAlexW4379523268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.